Vectus Biosystems Limited (VBS.AX)

0.0800 0.0000 (0.00%) At close: 03:54PM AEST

Vectus Biosystems Limited

Unit 5, 26-34 Dunning Avenue
Ground Floor
Rosebery, NSW 2018
Australia
61 2 8344 1300
https://www.vectusbiosystems.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Karen Annette Duggan	Chief Executive Officer	255.75k	N/A	N/A
Dr. Ivan Rajkovic Ph.D.	Interim Chief Technology Officer	N/A	N/A	N/A
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin	Company Secretary	N/A	N/A	N/A
Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D.	Consultant	10.83k	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; and VB4-A79 for the treatment of lung fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.

Corporate governance

Vectus Biosystems Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.